TI
INDP icon

Trexquant Investment’s Indaptus Therapeutics INDP Stock Holding History

Trexquant Investment’s Portfolio INDP Stock Details INDP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-6
Closed -$73K – 1218
2017
Q4 		$73K Buy
+6
New +$92.9K 0.01% 1016

Other funds holding INDP

ACP
Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
MIH
Meitav Investment House Bene-Beraq, Israel $9.12B AUM 42.07% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $6.91B AUM 19.7% 1-Year Est. Return
OAM
Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return
CC
Caxton Corporation Princeton, New Jersey $4.02M AUM 256.08% 1-Year Est. Return

Trexquant Investment's INDP Position: Q1 2018 in Review

Trexquant Investment sold out of Indaptus Therapeutics (INDP) in Q1 2018, closing a stake of 6 shares — an estimated $73K sold.

Trexquant Investment first reported a position in INDP in Q4 2017 and held it in 1 quarter. The position peaked at $73K in Q4 2017. 23 funds tracked by Wall St. Rank hold INDP as of Q1 2018.

  • Trexquant Investment reported no remaining Indaptus Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Trexquant Investment sold 6 Indaptus Therapeutics shares in Q1 2018, an estimated $73K.
  • Trexquant Investment first reported a position in Indaptus Therapeutics in Q4 2017 and held it in 1 quarter.
  • Trexquant Investment's Indaptus Therapeutics position peaked at $73K in Q4 2017.
  • 23 funds tracked by Wall St. Rank held Indaptus Therapeutics as of Q1 2018.

Based on Trexquant Investment's 13F filing for Q1 2018, filed 3 May 2018.